Global Leukemia Academy
Emerging and Practical Concepts and Controversies in Leukemias
Overview
In recent years progress in the molecular understanding of acute leukemias has led to greatly improved comprehension of these diseases, and novel approved therapies are changing treatment paradigms. Aptitude Health has developed the Global Leukemia Academy and is organizing a series of meetings in 2020 to help physicians better understand how the emerging therapies and concepts are being adapted globally, and to address barriers between innovation and implementation for patient care.
Date and Location
23–24 October 2020
Virtual Meeting
Meeting Content
View the slides and watch the video of the Day 1
ALL Plenary Session
Faculty
Patrick A. Brown, MD
Johns Hopkins University School of Medicine, USA
Dieter Hoelzer, MD, PhD
University of Frankfurt,
Germany
Elias Jabbour, MD
The University of Texas MD Anderson Cancer Center, USA
(Meeting Chair)
Franco Locatelli, MD, PhD
University of Rome
IRCCS Ospedale Pediatrico
Bambino Gesù, Italy
(Meeting Chair)
Rob Pieters, MD, PhD
Princess Máxima Center for Pediatric Oncology,
University of Utrecht, The Netherlands
José Maria Ribera, MD
Catalan Institute of
Oncology, University
Hospital Germans Trias i
Pujol, Spain
Philippe Rousselot, MD, PhD
University of Versailles Saint-Quentin-en-Yvelines,
France
|
Agenda |
The virtual program was held over 2 days with 3 sessions as follows. Day 1: Plenary Session ALL Day 2: Parallel breakout sessions – Adult ALL and Pediatric |
| DAY 1: Virtual Plenary sessions |
Time, CET | Title | Speaker |
| Friday, 23 October 2020 from 16.00 – 20.00 CET | 16.00 – 16.10 | Welcome and overview • Introduction to the voting system |
Elias Jabbour, Franco Locatelli |
| 16.10 – 16.25 | Review of prognostic value of MRD in ALL | Elias Jabbour | |
| 16.25 – 16.40 | How and when to check for MRD in ALL, including CR1 and CR2 | José Maria Ribera | |
| 16.40 – 16.55 | Genetic variants in ALL – Ph+ and Ph-like | Philippe Rousselot | |
| 16.55 – 17.15 | AYA ALL patients – what is the current treatment approach for this diverse patient population? | Rob Pieters | |
| 17.15 – 17.40 | Bispecific T-cell engagers as post-reinduction therapy improves survival in pediatric and AYA B-ALL | Patrick Brown | |
| 17.40 – 18.00 | Break | ||
| 18.00 – 18.45 | Panel discussion on the role of HSCT • Role of transplant in MRD+ population • Role of transplant in Salvage Setting • Discussion and voting Faculty panel: E. Jabbour, F. Locatelli, R. Pieters, J.M. Ribera, P. Rousselot, P. Brown, D. Hoelzer |
Philippe Rousselot, José Maria Ribera |
|
| 18.45 – 19.25 | Debate on CD19-targeted approaches • CAR T • Bispecifics • Discussion and voting Faculty panel: E. Jabbour, F. Locatelli, R. Pieters, J.M. Ribera, P. Rousselot, P. Brown, D. Hoelzer |
José Maria Ribera, Elias Jabbour |
|
| 19.25 – 19.55 | Emerging data and the management of ALL patients during COVID-19 • Presentation • Panel discussion Faculty panel: E. Jabbour, F. Locatelli, R. Pieters, J.M. Ribera, P. Rousselot, P. Brown, D. Hoelzer |
Elias Jabbour | |
| 19.55 – 20.00 | Session close | Elias Jabbour, Franco Locatelli |
| DAY 2: Virtual Breakout 1: Adult ALL patients |
Time, CET | Title | Speaker |
| 18.00 – 18.15 | Session open • Educational ARS questions for the audience |
Elias Jabbour | |
| 18.15 – 18.35 | Optimizing first-line therapy in adult and older ALL – integration of immunotherapy into frontline regimens •Presentation • Q&A |
Elias Jabbour | |
| 18.35 – 18.55 | Current treatment options for relapsed ALL in adult and elderly patients • Presentation • Q&A |
Dieter Hoelzer | |
| 18.55 – 19.45 | Case-based panel discussion Management of long- and short-term toxicities and treatment selection in adult and elderly patients • Case 1 • Case 2 • Discussion Faculty panel: E. Jabbour, D. Hoelzer, J.M. Ribera, P. Rousselot |
Philippe Rousselot, José Maria Ribera |
|
| 19.45 – 20.00 | Session close • Educational ARS questions for the audience |
Elias Jabbour |
| DAY 2: Virtual Breakout 2: Pediatric ALL patients |
Time, CET | Title | Speaker |
| Saturday, 24 October 2020 from 18.00 – 20.30 CET | 18.00 – 18.15 | Session open • Educational ARS questions for the audience |
Franco Locatelli |
| 18.15 – 18.45 | First-line treatment of pediatric ALL • Presentation • Q&A |
Rob Pieters | |
| 18.45 – 19.15 | Current treatment options for relapsed ALL in children, including HSCT and COVID-19 considerations • Presentation • Q&A |
Franco Locatelli | |
| 19.15 – 19.45 | Bispecific T-cell engagers for pediatric ALL • Presentation • Q&A |
Patrick Brown | |
| 19.45 – 20.15 | Case-based panel discussion Management of long- and short-term toxicities and treatment selection in pediatric patients • Case 1 • Case 2 • Discussion Faculty panel: R. Pieters, F. Locatelli, P. Brown |
Rob Pieters Patrick Brown |
|
| 20.15 – 20.30 | Session close • Educational ARS questions for the audience |
Franco Locatelli |
